NIAID is committed to advancing the understanding of autoimmune diseases such as type 1 diabetes and to conducting clinical studies to develop effective prevention and treatment strategies.
This is a two-part study to investigate the effect of intravenous Alpha-1 Antitrypsin (AAT) on preserving insulin-producing beta cell function and to determine if AAT will help slow the progression of type 1 diabetes.
Read more about this study and find site locations at the study website.
This study evaluates whether the drug alefacept will halt or slow the destruction of insulin-producing beta cells in the pancreas. This study is on-going but not recruiting volunteers.
Read more about this study and find site locations on ClinicalTrials.gov and at the study website.
See more NIAID-supported diabetes studies that are seeking volunteers on ClinicalTrials.gov.
The National Institute for Diabetes and Digestive and Kidney Diseases (NIDDK) also sponsors research related to type 1 diabetes. Find out more about NIDDK-supported Type 1 diabetes research, including studies currently recruiting participants.
Last Updated January 16, 2013